Literature DB >> 20628346

The role of radiotherapy in locally advanced pancreatic carcinoma.

Ruchika Gutt1, Stanley L Liauw, Ralph R Weichselbaum.   

Abstract

The prognosis for locally advanced pancreatic carcinoma remains dismal despite advances in chemotherapy and radiotherapy over the past few decades. The use of radiotherapy for pancreatic carcinoma is often disputed because of the hypothesis that patients with pancreatic cancer die from distant metastases. It is well accepted that the greatest chance for cure of pancreatic cancer involves surgical resection of the primary tumor. However, there is much controversy about the role of radiotherapy in local disease control. The aim of this Review is to discuss data from the available studies, both prospective and retrospective, that evaluate treatment options for locally advanced pancreatic cancer. We focus on the benefits associated with local therapies, including radiotherapy and surgical resection, as they relate to improved local disease control, prolonged overall survival and improved symptom control.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20628346     DOI: 10.1038/nrgastro.2010.98

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  114 in total

1.  The use of active breathing control (ABC) to reduce margin for breathing motion.

Authors:  J W Wong; M B Sharpe; D A Jaffray; V R Kini; J M Robertson; J S Stromberg; A A Martinez
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-07-01       Impact factor: 7.038

2.  Effect on local control and survival of electron beam intraoperative irradiation for resectable pancreatic adenocarcinoma.

Authors:  M Reni; M G Panucci; A J Ferreri; G Balzano; P Passoni; G M Cattaneo; S Cordio; U Scaglietti; A Zerbi; G L Ceresoli; C Fiorino; R Calandrino; C Staudacher; E Villa; V Di Carlo
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-07-01       Impact factor: 7.038

3.  Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement.

Authors:  Ross A Abrams; Andrew M Lowy; Eileen M O'Reilly; Robert A Wolff; Vincent J Picozzi; Peter W T Pisters
Journal:  Ann Surg Oncol       Date:  2009-04-24       Impact factor: 5.344

Review 4.  A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer.

Authors:  Alessio G Morganti; Mariangela Massaccesi; Giuseppe La Torre; Luciana Caravatta; Adele Piscopo; Rosa Tambaro; Luigi Sofo; Giuseppina Sallustio; Marcello Ingrosso; Gabriella Macchia; Francesco Deodato; Vincenzo Picardi; Edy Ippolito; Numa Cellini; Vincenzo Valentini
Journal:  Ann Surg Oncol       Date:  2009-10-24       Impact factor: 5.344

5.  Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma.

Authors:  Morten Hoyer; Henrik Roed; Lisa Sengelov; Anders Traberg; Lars Ohlhuis; Jorgen Pedersen; Hanne Nellemann; Anne Kiil Berthelsen; Frey Eberholst; Svend Aage Engelholm; Hans von der Maase
Journal:  Radiother Oncol       Date:  2005-07       Impact factor: 6.280

6.  Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma.

Authors:  Jerome Landry; Paul J Catalano; Charles Staley; Wayne Harris; John Hoffman; Mark Talamonti; Natalie Xu; Harry Cooper; Al B Benson
Journal:  J Surg Oncol       Date:  2010-06-01       Impact factor: 3.454

7.  Chemoradiotherapy for locally advanced pancreatic cancer: a radiotherapy dose escalation and organ motion study.

Authors:  A M Henry; W D J Ryder; C Moore; D J Sherlock; J I Geh; P Dunn; P Price
Journal:  Clin Oncol (R Coll Radiol)       Date:  2008-06-18       Impact factor: 4.126

8.  Treatment of pancreatic cancer tumors with intensity-modulated radiation therapy (IMRT) using the volume at risk approach (VARA): employing dose-volume histogram (DVH) and normal tissue complication probability (NTCP) to evaluate small bowel toxicity.

Authors:  Jerome C Landry; Gary Y Yang; Joseph Y Ting; Charles A Staley; William Torres; Natia Esiashvili; Lawrence W Davis
Journal:  Med Dosim       Date:  2002       Impact factor: 1.482

9.  Translational strategies exploiting TNF-alpha that sensitize tumors to radiation therapy.

Authors:  H J Mauceri; M A Beckett; H Liang; H G Sutton; S Pitroda; E Galka; E Efimova; T Darga; N N Khodarev; C R King; M C Posner; S Hellman; D W Kufe; R R Weichselbaum
Journal:  Cancer Gene Ther       Date:  2008-10-31       Impact factor: 5.987

10.  Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma.

Authors:  Kimberly M Brown; Veeriah Siripurapu; Marson Davidson; Steven J Cohen; Andre Konski; James C Watson; Tiaynu Li; Vince Ciocca; Harry Cooper; John P Hoffman
Journal:  Am J Surg       Date:  2008-03       Impact factor: 2.565

View more
  19 in total

1.  Genetic effects and modifiers of radiotherapy and chemotherapy on survival in pancreatic cancer.

Authors:  Hongmei Zeng; Herbert Yu; Lingeng Lu; Dhanpat Jain; Mark S Kidd; M Wasif Saif; Stephen J Chanock; Patricia Hartge; Harvey A Risch
Journal:  Pancreas       Date:  2011-07       Impact factor: 3.327

2.  K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas.

Authors:  Feng Wei; Yan Liu; Anita C Bellail; Jeffrey J Olson; Shi-Yong Sun; Guoyue Lu; Lijuan Ding; Changji Yuan; Guangyi Wang; Chunhai Hao
Journal:  Cancer Lett       Date:  2012-02-14       Impact factor: 8.679

3.  Antibody against CD44s inhibits pancreatic tumor initiation and postradiation recurrence in mice.

Authors:  Ling Li; Xinbao Hao; Jun Qin; Wenhua Tang; Fengtian He; Amber Smith; Min Zhang; Diane M Simeone; Xiaotan T Qiao; Zhi-Nan Chen; Theodore S Lawrence; Liang Xu
Journal:  Gastroenterology       Date:  2014-01-05       Impact factor: 22.682

4.  Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation.

Authors:  Sunil Krishnan; Awalpreet S Chadha; Yelin Suh; Hsiang-Chun Chen; Arvind Rao; Prajnan Das; Bruce D Minsky; Usama Mahmood; Marc E Delclos; Gabriel O Sawakuchi; Sam Beddar; Matthew H Katz; Jason B Fleming; Milind M Javle; Gauri R Varadhachary; Robert A Wolff; Christopher H Crane
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-12-11       Impact factor: 7.038

5.  Personalized medicine in pancreatic cancer: prognosis and potential implications for therapy.

Authors:  Christine A Iacobuzio-Donahue
Journal:  J Gastrointest Surg       Date:  2012-06-29       Impact factor: 3.452

6.  Rare long-term survivors of pancreatic adenocarcinoma without curative resection.

Authors:  Stephen Y Oh; Alicia Edwards; Margaret T Mandelson; Bruce Lin; Russell Dorer; W Scott Helton; Richard A Kozarek; Vincent J Picozzi
Journal:  World J Gastroenterol       Date:  2015-12-28       Impact factor: 5.742

7.  Segmentation precision of abdominal anatomy for MRI-based radiotherapy.

Authors:  Camille E Noel; Fan Zhu; Andrew Y Lee; Hu Yanle; Parag J Parikh
Journal:  Med Dosim       Date:  2014-04-13       Impact factor: 1.482

8.  Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation.

Authors:  Daniel W Golden; Caroline J Novak; Bruce D Minsky; Stanley L Liauw
Journal:  Radiat Oncol       Date:  2012-09-13       Impact factor: 3.481

Review 9.  Technical advances in endoscopic ultrasound-guided fiducial placement for the treatment of pancreatic cancer.

Authors:  Disaya Chavalitdhamrong; Christopher J DiMaio; Peter D Siersema; Mihir S Wagh
Journal:  Endosc Int Open       Date:  2015-07-21

10.  Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery.

Authors:  Lisa Buckel; Elamprakash N Savariar; Jessica L Crisp; Karra A Jones; Angel M Hicks; Daniel J Scanderbeg; Quyen T Nguyen; Jason K Sicklick; Andrew M Lowy; Roger Y Tsien; Sunil J Advani
Journal:  Cancer Res       Date:  2015-02-13       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.